PVLA at a glance
PALVELLA THERAPEUTICS, INC. (PVLA, SEC CIK 1583648) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2023 (FY2023), PALVELLA THERAPEUTICS, INC. (PVLA) reported revenue of $42.8 million and a net loss of $24.5 million. Diluted EPS was $2.17.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding PALVELLA THERAPEUTICS, INC. (PVLA) shares worth $595.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Goin Kathleen on September 16, 2026 of 989 shares at $152.36 per share.
- In the last 90 days, PVLA insiders reported 0 open-market purchases ($0) and 22 open-market sales ($6.2M) on Form 4, a net sale of $6.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2023
- $42.8M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 22 sells
- Net −$6.2M
- 13F holders
- 27 funds
- $595.9M · +1 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor changes from the 2025 Form 10-K
- Change-in-control risk: August 3, 2026 policy accelerates unvested equity vesting after qualifying terminations
- Regulatory compliance risk: Rule 10b5-1 plan permits director sales of up to 55,000 shares
- Governance risk: policy covers vice presidents and above, including named executive officers
- Equity dilution risk: performance-based awards generally vest at target performance upon qualifying change in control
AI summary of the PVLA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 contains only incorporation-by-reference and liability disclaimers
- No operating results, financial figures, reporting period, or earnings release content provided
Item 7.01: Regulation FD Disclosure
- Earnings call scheduled for August 4, 2026 with accompanying investor presentation
- Exhibit 99.2 contains presentation materials relevant to the company’s earnings update
Item EX-99.1: Item EX-99.1
- Q2 2026 results: $21.9M net loss, or $1.52 per share, versus $9.5M and $0.86 in Q2 2025
- Cash, equivalents and short-term investments of $250.6M support ongoing clinical development and planned commercialization activities
Item 8.01: Other Events
- Corporate presentation posted July 14, 2026 for use in investor meetings
- Exhibit 99.1 contains the substantive company and pipeline information
Item EX-99.1: Item EX-99.1
- NDA submission on track for 2H 2026, with potential FDA approval and U.S. launch in 1H 2027 for microcystic lymphatic malformations
- Phase 3 SELVA delivered statistically significant results across primary, key secondary, and four secondary endpoints, all p<0.001
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from seven to eight members with Matthew Pauls appointed as a Class I director through the 2027 annual meeting
- Independent director brings public biopharma leadership, commercialization, clinical development, and rare-disease experience
AI summaries of PVLA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PVLA
Don't miss the next PVLA filing
- Alerts as it files. A push when PVLA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PVLA, by share count.
- Ask anything. An AI agent that reads every PVLA filing and answers with sources.
PVLA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Goin Kathleen | M | Sep 16, 2026 | 2,148 | - |
| Goin Kathleen | M | Sep 16, 2026 | 2,154 | - |
| Goin Kathleen | M | Sep 16, 2026 | 2,154 | $7.14 |
| Goin Kathleen | M | Sep 16, 2026 | 2,148 | $9.08 |
| Goin Kathleen | Sell | Sep 16, 2026 | 989 | $152.36 |
| Goin Kathleen | Sell | Sep 16, 2026 | 1,654 | $153.24 |
| Goin Kathleen | Sell | Sep 16, 2026 | 1,659 | $151.16 |
| JENKINS GEORGE M | Sell | Sep 15, 2026 | 954 | $149.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $42.8M | - | - |
| Operating Income | -$29.8M | -$14.1M | -$38.6M |
| Net Income | -$24.5M | -$17.4M | -$41.7M |
| Op. Margin | -69.5% | - | - |
| Net Margin | -57.3% | - | - |
| Balance Sheet | |||
| Total Assets | $38.7M | $88.2M | $59.6M |
| Equity | $26.8M | $62.6M | $28.0M |
| ROE | -91.7% | -27.8% | -149.1% |
| Per Share | |||
| EPS | $2.17 | $-7.83 | $-3.71 |
| Cash Flow | |||
| Operating CF | -$53.8M | -$10.8M | -$25.0M |
| CapEx | $171K | - | - |
Source: XBRL data in PALVELLA THERAPEUTICS, INC. (PVLA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PVLA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $595.9M |
| Q1 2026 | 26 | $377.7M |
| Q4 2025 | 22 | $243.6M |
| Q3 2025 | 21 | $119.0M |
| Q2 2025 | 15 | $31.0M |
| Q1 2025 | 10 | $13.7M |
| Q4 2024 | 5 | $520,000 |
- T. Rowe Price Group+236.3K (+59%)
- BlackRock+231.5K (+34%)
- State Street Corp+194.2K (+42%)
- Morgan Stanley+53.4K (+42%)
- Vanguard Portfolio Management LLC+38.1K (+42%)
- Millennium Management−41.4K (-44%)
- Citadel Advisors LLC−17.0K (-83%)
- Invesco Ltd−14.9K (-31%)
- Raymond James Financial−1.8K (-7%)
- FMR LLC (Fidelity)−967 (-0%)
- Mangrove Partners−1.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 126 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PVLA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| SC 13G | Aug 10, 2026 | - | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 3, 2026 | - | - | |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PVLA SEC filings: frequently asked questions
Are PVLA insiders buying or selling?
In the last 90 days, PALVELLA THERAPEUTICS, INC. (PVLA) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $6.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PVLA stock?
As of June 30, 2026, the largest PALVELLA THERAPEUTICS, INC. (PVLA) holders among the 13F filers tracked by SignalX were BlackRock ($140.3 million), State Street Corp ($99.8 million), T. Rowe Price Group ($97.6 million), Vanguard Capital Management LLC ($78.5 million), FMR LLC (Fidelity) ($32.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PVLA's revenue in fiscal year 2023?
For the fiscal year ended December 31, 2023 (FY2023), PALVELLA THERAPEUTICS, INC. (PVLA) reported revenue of $42.8 million and a net loss of $24.5 million. Diluted EPS was $2.17. The figures come from the XBRL data in the 10-K.
What did PVLA report in its latest 8-K?
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Item 2.02 contains only incorporation-by-reference and liability disclaimers.
What are the latest PVLA SEC filings?
PALVELLA THERAPEUTICS, INC. (PVLA) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 18, 2026.
What is PVLA's SEC CIK number?
PALVELLA THERAPEUTICS, INC. (PVLA)'s SEC Central Index Key (CIK) is 1583648. EDGAR lists every PVLA filing under that number.
Ask anything about PVLA
The research agent reads PVLA's filings, financials, insider trades and 13F holders, then answers with sources.